Spots Global Cancer Trial Database for paediatric
Every month we try and update this database with for paediatric cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| PRecISion Medicine for Children With Cancer | NCT03336931 | Childhood Cance... Childhood Solid... Childhood Brain... Childhood Leuke... Refractory Canc... Relapsed Cancer | Molecular profi... | - 21 Years | Sydney Children's Hospitals Network | |
| CD19-CAR Immunotherapy for Childhood Acute Lymphoblastic Leukemia (ALL) | NCT01195480 | Acute Lymphobla... | donor-derived E... Irradiated dono... | - 18 Years | University College, London | |
| DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers. | NCT05770544 | Solid Tumor Haematological ... Malignancy Malignant Neopl... Lymphoprolifera... Neoplasms by Hi... Neoplasms by Si... Cancer Brain Neoplasms Melanoma Glioma | Entrectinib | - | Cancer Research UK | |
| Precision Medicine for Every Child With Cancer | NCT05504772 | Childhood Cance... Childhood Solid... Childhood Brain... Childhood Leuke... Refractory Canc... Relapsed Cancer | Whole Genome Se... RNA seq DNA Methylation Targeted Panel ... High Throughput... Patient Derived... Liquid Biopsy | 0 Years - 25 Years | Australian & New Zealand Children's Haematology/Oncology Group | |
| A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis | NCT03969329 | Secondary Hyper... | Etelcalcetide | 2 Years - 17 Years | Amgen | |
| Isolated Vascularized Gastric Tube Biliary Enteric Drainage: A Paediatric Case Series Experience. | NCT04319302 | Biliary Obstruc... Choledochal Cys... | Isolated Vascul... | - 12 Years | University of KwaZulu | |
| Minimising Adverse Drug Reactions and Verifying Economic Legitimacy in Children (MARVEL-PIC) | NCT05667766 | Neoplasms Bone Marrow Tra... | Release of Exte... Release of Exte... | - 18 Years | Murdoch Childrens Research Institute | |
| Immunoadsorption Therapy in Managing NMDAR Antibodies Encephalitis | NCT03274375 | Anti-NMDAR Ence... | IA session Rituximab | - 18 Years | Assistance Publique - Hôpitaux de Paris | |
| Effect and Safety of Ocoxin Oral Solution on the Quality of Life of Paediatric Patients With Advanced Stage Solid Tumours | NCT06363201 | Advanced Cancer Advanced Solid ... Lymphoma, Hodgk... Central Nervous... Sarcoma Germ Cell Tumor Pediatric Cance... | Ocoxin Oral sol... | 7 Years - 18 Years | Catalysis SL | |
| Effect and Safety of Ocoxin Oral Solution on the Quality of Life of Paediatric Patients With Advanced Stage Solid Tumours | NCT06363201 | Advanced Cancer Advanced Solid ... Lymphoma, Hodgk... Central Nervous... Sarcoma Germ Cell Tumor Pediatric Cance... | Ocoxin Oral sol... | 7 Years - 18 Years | Catalysis SL | |
| Health and Exercise Response in Children With Chronic and Auto-immune Pathologies | NCT03913962 | Juvenile Idiopa... Diabetes Inflammatory Bo... Cancer Survivor Anorexia Nervos... | indirect calori... | 6 Years - 18 Years | University Hospital, Clermont-Ferrand | |
| Beat to Beat A Study in Paediatric, Adolescent and Young Adult Patients Who Are Undergoing or Have Undergone Cancer Therapy to Evaluate the Agreement Between QTc Measured Using 12 Lead Electrocardiogram (ECG) and a Wearable Device ECG | NCT05615376 | Neoplasms Cardiac Arrhyth... | ECG application 12 lead ECG | 7 Years - 18 Years | Murdoch Childrens Research Institute | |
| Cinacalcet in Paediatric Secondary Hyperparathyroidism (SHPT) Due to Chronic Kidney Disease (CKD) | NCT01479088 | Secondary Hyper... | Cinacalcet HCl | 2 Years - 18 Years | Istituto Giannina Gaslini | |
| Retrospective Review on PAEDIATRIC and ADOLESCENT ADNEXAL MASSES | NCT05461872 | Adnexal Mass | No intervention | 1 Day - 21 Years | Chinese University of Hong Kong | |
| A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN) | NCT04590235 | Neurofibromatos... Neurofibroma Pl... | Selumetinib | 3 Years - 99 Years | AstraZeneca | |
| Studying Conditioning Regimen In Pediatric Transplantation - AML , SCRIPT-AML | NCT05477589 | Acute Myeloid L... Stem Cell Trans... | busulfan, cyclo... clofarabine, fl... | - 18 Years | Vastra Gotaland Region | |
| Immunoadsorption Therapy in Managing NMDAR Antibodies Encephalitis | NCT03274375 | Anti-NMDAR Ence... | IA session Rituximab | - 18 Years | Assistance Publique - Hôpitaux de Paris | |
| Precision Medicine for Every Child With Cancer | NCT05504772 | Childhood Cance... Childhood Solid... Childhood Brain... Childhood Leuke... Refractory Canc... Relapsed Cancer | Whole Genome Se... RNA seq DNA Methylation Targeted Panel ... High Throughput... Patient Derived... Liquid Biopsy | 0 Years - 25 Years | Australian & New Zealand Children's Haematology/Oncology Group | |
| Effect and Safety of Ocoxin Oral Solution on the Quality of Life of Paediatric Patients With Advanced Stage Solid Tumours | NCT06363201 | Advanced Cancer Advanced Solid ... Lymphoma, Hodgk... Central Nervous... Sarcoma Germ Cell Tumor Pediatric Cance... | Ocoxin Oral sol... | 7 Years - 18 Years | Catalysis SL | |
| Studying Conditioning Regimen In Pediatric Transplantation - AML , SCRIPT-AML | NCT05477589 | Acute Myeloid L... Stem Cell Trans... | busulfan, cyclo... clofarabine, fl... | - 18 Years | Vastra Gotaland Region | |
| Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer | NCT06208657 | Childhood Cance... Childhood Solid... Childhood Brain... Recurrent Cance... Refractory Canc... | Paxalisib, Irin... Pimasertib | 0 Years - 21 Years | Australian & New Zealand Children's Haematology/Oncology Group | |
| Retrospective Review on PAEDIATRIC and ADOLESCENT ADNEXAL MASSES | NCT05461872 | Adnexal Mass | No intervention | 1 Day - 21 Years | Chinese University of Hong Kong | |
| A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis | NCT03969329 | Secondary Hyper... | Etelcalcetide | 2 Years - 17 Years | Amgen | |
| Controlling Coordination After Childhood Cerebellar Cancer, a Pilot Study | NCT04501731 | Brain Cancer | Transcranial Ma... Magnetic Resona... Motor assessmen... Questionnaires | 16 Years - 22 Years | University of Nottingham | |
| Study to Evaluate Cinacalcet in Children With Chronic Kidney Disease | NCT01290029 | Chronic Kidney ... Hyperparathyroi... Secondary Hyper... | Cinacalcet | 28 Days - 2190 Days | Amgen | |
| A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis | NCT03969329 | Secondary Hyper... | Etelcalcetide | 2 Years - 17 Years | Amgen | |
| CD19-CAR Immunotherapy for Childhood Acute Lymphoblastic Leukemia (ALL) | NCT01195480 | Acute Lymphobla... | donor-derived E... Irradiated dono... | - 18 Years | University College, London | |
| DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers. | NCT05770544 | Solid Tumor Haematological ... Malignancy Malignant Neopl... Lymphoprolifera... Neoplasms by Hi... Neoplasms by Si... Cancer Brain Neoplasms Melanoma Glioma | Entrectinib | - | Cancer Research UK | |
| DWI in the Diagnosis of Histological Types of Nephroblastoma in Children | NCT04814758 | Nephroblastoma ... | MRI DWI sequenc... | 6 Days - 18 Years | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | |
| Propofol vs Sevo for Paediatric Tumor Surgery | NCT04475705 | Solid Tumor Carcinoma Malignancy Cancer | propofol sevoflurane | 6 Months - 18 Years | Hong Kong Children's Hospital | |
| DWI in the Diagnosis of Histological Types of Nephroblastoma in Children | NCT04814758 | Nephroblastoma ... | MRI DWI sequenc... | 6 Days - 18 Years | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | |
| Study to Evaluate Cinacalcet in Children With Chronic Kidney Disease | NCT01290029 | Chronic Kidney ... Hyperparathyroi... Secondary Hyper... | Cinacalcet | 28 Days - 2190 Days | Amgen |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
